Apyx Medical Posts 28% Surgical Aesthetics Growth on AYON Demand
Event summary
- Q2 2026 revenue hit $13.9M, up 22% YoY, driven by 28% growth in Surgical Aesthetics segment.
- AYON platform's limited commercial launch of power liposuction handpiece began in June 2026.
- Reaffirmed FY2026 revenue guidance at $59M–$60M, up from $52.8M in 2025.
- Adjusted EBITDA loss narrowed to $0.7M from $2.0M YoY.
The big picture
Apyx Medical's Q2 results highlight the growing demand for its AYON platform in surgical aesthetics, a segment increasingly prioritized over OEM revenue. The FDA clearance for power liposuction expands AYON's capabilities, aligning with broader industry trends toward integrated body contouring solutions. With $27.6M in cash reserves and guidance reaffirmation, the company aims to leverage clinical data and commercial rollouts to drive full-year performance.
What we're watching
- Product Adoption
- The pace at which AYON's power liposuction handpiece gains traction among key surgeons will determine H2 2026 momentum.
- Segment Shift
- Whether Apyx can sustain Surgical Aesthetics growth while OEM revenue declines further remains a strategic pivot point.
- Cost Management
- How effectively the company controls operating expenses will impact its path to profitability amid reaffirmed guidance.
Related topics